Myths and challenges around anticoagulation in atrial fibrillation: A practicing clinician's perspective

KEJA: Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Research grants from the Finnish Foundation for Cardiovascular Research and Clinical Research Fund of Turku University Hospital; VL: Speaker: Boehringer-Ingelheim. Research grant from the State Research Funding of the Turku University Hospital expert responsibility area; KT: none. GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, and Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-PI of the AFFIRMO project on multimorbidity in AF (grant agreement No 899871), TARGET project on digital twins for personalized management of atrial fibrillation and stroke (grant agreement No 101136244) and ARISTOTELES project on artificial intelligence for management of chronic long-term conditions (grant agreement No 101080189), which are all funded by the EU's Horizon Europe Research & Innovation programme. Perspective article is based on interpretation of the articles in the reference list. Data used to support the findings of this study are available from the corresponding author upon request.